Indications and uses
Controls symptoms of diarrhea, including Travelers’ Diarrhea
Controls symptoms of diarrhea, including Travelers’ Diarrhea
drink plenty of clear fluids to help prevent dehydration caused by diarrhea find right dose on chart. If possible, use weight to dose; otherwise, use age. adults and children 12 years and over 2 caplets after the first loose stool; 1 caplet after each subsequent loose stool; but no more than 4 caplets in 24 hours children 9-11 years (60-95 lbs) 1 caplet after the first loose stool; ½ caplet after each subsequent l...
Loperamide HCI USP, 2 mg
Anti-diarrheal
Controls symptoms of diarrhea, including Travelers’ Diarrhea
Allergy alert: Do not use if you have ever had a rash or other allergic reaction to loperamide HCI
If you have bloody or black stool
Taking antibiotics
Ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away.
| adults and children 12 years and over | 2 caplets after the first loose stool; 1 caplet after each subsequent loose stool; but no more than 4 caplets in 24 hours |
| children 9-11 years (60-95 lbs) | 1 caplet after the first loose stool; ½ caplet after each subsequent loose stool; but no more than 3 caplets in 24 hours |
| children 6-8 years (48-59 lbs) | 1 caplet after the first loose stool; ½ caplet after each subsequent loose stool; but no more than 2 caplets in 24 hours |
| children under 6 years (up to 47 lbs) | ask a doctor |
Anhydrous lactose, croscarmellose sodium, crospovidone, D&C yellow no.10, FD&C blue no.1, hydrogenated vegetable oil, magnesium stearate, powdered cellulose, pregelatinized starch
Call 1800-406-7984
select brand®
NDC 15127-338-12
Loperamide Hydrochloride Tablets USP, 2 mg
ANTI-DIARRHEAL
Controls The Symptoms Of Diarrhea
٭Compare to the active ingredient of Imodium®A-D
12 Caplets*
Each Caplet (*capsule-shaped tablet) contains Loperamide HCl USP, 2 mg
5048836/R1109

| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 10f838ef-a72b-645d-80f8-e2255205c3b1 | Product name | 6 | 20240805 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 15127-338-12 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-2e78-f424-e053-dadaa90a57ce | Drug Facts |
| 15127-338-66 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-2e78-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 15127-338-12 | EA - Each | 15127-338 | bf1bbe6a-9fb0-42a5-9f0f-014abfb3f6e2 | 1 | 2013-02-13 |
| 15127-338-66 | EA - Each | 15127-338 | dc5ac78e-6882-4d8d-ac3d-bd32add7d4c5 | 1 | 2013-02-13 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | ACTIVE INGREDIENT | 77TI35393C | 1 | |
| LOPERAMIDE | ACTIVE MOIETY | 6X9OC3H4II | 1 | |
| ANHYDROUS LACTOSE | INACTIVE INGREDIENT | 3SY5LH9PMK | 1 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | 1 | |
| CROSPOVIDONE | INACTIVE INGREDIENT | 68401960MK | 1 | |
| D&C YELLOW NO. 10 | INACTIVE INGREDIENT | 35SW5USQ3G | 1 | |
| FD&C BLUE NO. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| POWDERED CELLULOSE | INACTIVE INGREDIENT | SMD1X3XO9M | 1 | |
| STARCH, PREGELATINIZED CORN | INACTIVE INGREDIENT | O8232NY3SJ | 1 | |
| TRISTEARIN | INACTIVE INGREDIENT | P6OCJ2551R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 15127-338 | 15127-338-66, 15127-338-12 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | 77TI35393C | ACTIB |
| ANHYDROUS LACTOSE | 3SY5LH9PMK | IACT |
| CROSCARMELLOSE SODIUM | M28OL1HH48 | IACT |
| CROSPOVIDONE | 68401960MK | IACT |
| D&C YELLOW NO. 10 | 35SW5USQ3G | IACT |
| FD&C BLUE NO. 1 | H3R47K3TBD | IACT |
| TRISTEARIN | P6OCJ2551R | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| POWDERED CELLULOSE | SMD1X3XO9M | IACT |
| STARCH, PREGELATINIZED CORN | O8232NY3SJ | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | LIQUID / TOPICAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CONCENTRATE / ORAL | NA | ||
| POWDERED CELLULOSE | POWDERED CELLULOSE | SMD1X3XO9M | TABLET, CHEWABLE / ORAL | NA | ||
| POWDERED CELLULOSE | POWDERED CELLULOSE | SMD1X3XO9M | DISC / TOPICAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOLUTION / TOPICAL | 0.01 %w/w | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET / SUBLINGUAL | 0.23 mg | ||
| POWDERED CELLULOSE | POWDERED CELLULOSE | SMD1X3XO9M | TABLET / SUBLINGUAL | 4.5 mg | ||
| ANHYDROUS LACTOSE | ANHYDROUS LACTOSE | 3SY5LH9PMK | CAPSULE, DELAYED RELEASE / ORAL | 360 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, EXTENDED RELEASE / ORAL | 117 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| POWDERED CELLULOSE | POWDERED CELLULOSE | SMD1X3XO9M | LIQUID / ORAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | FILM / SUBLINGUAL | 0.07 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION / ORAL | 64 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | MOUTHWASH / BUCCAL | NA | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | CAPSULE, EXTENDED RELEASE / ORAL | 3 mg | ||
| STARCH, PREGELATINIZED CORN | STARCH, CORN | O8232NY3SJ | TABLET, COATED / ORAL | 256 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, SUGAR COATED / ORAL | NA | ||
| POWDERED CELLULOSE | POWDERED CELLULOSE | SMD1X3XO9M | TABLET, EXTENDED RELEASE / ORAL | 156 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | POWDER, FOR SOLUTION / ORAL | NA | ||
| ANHYDROUS LACTOSE | ANHYDROUS LACTOSE | 3SY5LH9PMK | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 375 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET / ORAL | 27.53 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TROCHE / ORAL | 50 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, FILM COATED / ORAL | 330 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SOAP / TOPICAL | 1.4 %w/w | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, DELAYED RELEASE / ORAL | 0.01 mg | ||
| STARCH, PREGELATINIZED CORN | STARCH, CORN | O8232NY3SJ | POWDER, FOR SUSPENSION / ORAL | 34 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, EXTENDED RELEASE / ORAL | 392 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SUSPENSION / ORAL | 1 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | GUM, CHEWING / BUCCAL | 24 mg | ||
| ANHYDROUS LACTOSE | ANHYDROUS LACTOSE | 3SY5LH9PMK | TABLET, CHEWABLE / ORAL | 2850 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CONCENTRATE / BUCCAL | NA | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | POWDER / ORAL | 48 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, COATED / ORAL | 224 mg | ||
| ANHYDROUS LACTOSE | ANHYDROUS LACTOSE | 3SY5LH9PMK | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 25 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, COATED / ORAL | 0.52 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET, DELAYED RELEASE / ORAL | 1.9 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | GEL / TOPICAL | NA | ||
| ANHYDROUS LACTOSE | ANHYDROUS LACTOSE | 3SY5LH9PMK | POWDER, FOR SUSPENSION / ORAL | 469 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SOLUTION / ORAL | 8 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET, COATED / ORAL | 2.5 mg | ||
| POWDERED CELLULOSE | POWDERED CELLULOSE | SMD1X3XO9M | POWDER, FOR SUSPENSION / ORAL | 1600 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | TABLET, EXTENDED RELEASE / ORAL | 4 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | RING / VAGINAL | 2 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | GUM, CHEWING / ORAL | 2 mg | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | POWDER, FOR SUSPENSION / ORAL | 1 mg/5ml | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | ELIXIR / ORAL | 0.3 mg/15ml | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | ELIXIR / ORAL | NA | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 64 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| STARCH, PREGELATINIZED CORN | STARCH, CORN | O8232NY3SJ | CONCENTRATE / ORAL | NA | ||
| STARCH, PREGELATINIZED CORN | STARCH, CORN | O8232NY3SJ | DROPS / ORAL | NA | ||
| FD&C BLUE NO. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CREAM / TOPICAL | 0.01 %w/w | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| STARCH, PREGELATINIZED CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION, EXTENDED RELEASE / ORAL | 113 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INSERT / VAGINAL | 69 mg | ||
| STARCH, PREGELATINIZED CORN | STARCH, CORN | O8232NY3SJ | TABLET / SUBLINGUAL | 409 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A074091-001 | LOPERAMIDE HYDROCHLORIDE | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | c2088c7a36db… | ||
| 2026-09-14 22:38:34 | 2026-08 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074091-001 | LOPERAMIDE HYDROCHLORIDE | 2MG | TABLET / ORAL | 1992-12-10 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e887e062-0b65-4612-b0bf-ea04f01cdbdb | 6d086c18-eb09-46ec-9628-2d8676c17c7c | 2012-09-27 | Warnings | e887e062-0b65-4612-b0bf-ea04f01cdbdb 6d086c18-eb09-46ec-9628-2d8676c17c7c |
Adverse event summaries are temporarily unavailable. Other product information remains available.